Drug name - Rinvoq
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE47221 | ABBVIE INC | Tricyclic compounds |
Dec, 2030
(8 years from now) | |
| US8962629 | ABBVIE INC | Tricyclic compounds |
Jan, 2031
(8 years from now) | |
| US10981923 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US9951080 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US11186584 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| CN102118968A | ABBVIE INC | Novel Tricyclic Compounds |
Sep, 2015
(7 years ago) | |
| CN104592231A | ABBVIE INC | Novel Tricyclic Compounds |
Jan, 2019
(3 years ago) | |
| CN104370909B | ABBVIE INC | Tricyclic Compounds |
Dec, 2030
(8 years from now) | |
| CN109053742A | ABBVIE INC | Novel Tricyclic Compounds |
Dec, 2030
(8 years from now) | |
| CN104370909A | ABBVIE INC | Novel Tricyclic Compounds |
Dec, 2030
(8 years from now) | |
| CN102711476A | ABBVIE INC | Novel Tricyclic Compounds |
Dec, 2030
(8 years from now) | |
| CN102711476B | ABBVIE INC | Novel Tricyclic Compounds |
Dec, 2030
(8 years from now) | |
| CN109053742B | ABBVIE INC | Tricyclic Compounds |
Dec, 2030
(8 years from now) | |
| IN292307B | ABBVIE INC | Novel Tricyclic Compounds |
Jun, 2029
(6 years from now) | |
| IN201100195P1 | ABBVIE INC | Novel Tricyclic Compounds |
Jun, 2029
(6 years from now) | |
| EP2299821A1 | ABBVIE INC | Tricyclic Compounds |
Jun, 2029
(6 years from now) | |
| EP2299821A4 | ABBVIE INC | Novel Tricyclic Compounds |
Jun, 2029
(6 years from now) | |
| EP2299821B1 | ABBVIE INC | Tricyclic Compounds |
Jun, 2029
(6 years from now) | |
| EP2506716B1 | ABBVIE INC | Novel Tricyclic Compounds |
Dec, 2030
(8 years from now) | |
| EP2506716A1 | ABBVIE INC | Novel Tricyclic Compounds |
Dec, 2030
(8 years from now) | |
| EP2506716A4 | ABBVIE INC | Novel Tricyclic Compounds |
Dec, 2030
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10550126 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US10995095 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US10597400 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US9963459 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US10981924 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US10519164 | ABBVIE INC | Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US10344036 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US11198697 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
| US10730883 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(14 years from now) | |
Drugs and Companies using UPADACITINIB ingredient
Treatment: Treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, or when use of those therapies are inadvisable; Treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tnf blockers
Dosage: TABLET, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 15MG | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| 30MG | TABLET, EXTENDED RELEASE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.